So, HR status did not impact the standard of anti-HER2 agents and chemotherapy in metastatic HER2+ BC in first- and second-line therapies, while in third- or later-line therapies, the regimen of FHAbe was restricted to HR+ BC in monarcHER (45). Here, ERBB2 is linked to breast cancer.